Skip to main content

News

News

| Article
Pharmacogenetic Testing Studie der Harvard Medical School

Studie der Harvard Medical School zeigt, dass pharmakogenetische Tests auf Statin-Nebenwirkungen nicht zu einem schlechteren Cholesterinspiegel im Blut führen.

"Diese Studie gibt Gewissheit, dass Patienten und Anbieter von pharmakogenetischen Tests die Ergebnisse so einsetzen können, dass ihr Nutzen maximiert und schädliche unbeabsichtigte Folgen vermieden werden", sagte der Hauptautor Jason Vassy, ​​Assistenzprofessor für Medizin in Harvard, in einer Erklärung.

Mehr erfahren ...

Zum Artikel auf genomeweb

Read more about Pharmacogenetic Testing Studie der Harvard Medical School >
| Article
Pharmacogenetic Testing Study from Harvard Medical School

Study from Harvard Medical School reveals that Pharmacogenetic Testing for Statin Side Effects Doesn't Result in Worse Blood Cholesterol Levels.

"This study provides reassurance that patients and providers can use pharmacogenetic testing in a way that maximizes its benefits while avoiding harmful unintended consequences," lead author Jason Vassy, an assistant professor of medicine at Harvard, said in a statement."

Lern more ...

Article on genomeweb

Read more about Pharmacogenetic Testing Study from Harvard Medical School >
| Article
Personalisierte Medizin in Hessen - Company Profile bio.logis GIM

The brochure "Personalized Medicine in Hessen" has been published as an updated new edition. Read a company profile about bio.logis GIM in it. You can download brochure, published by Hessen Trade & Invest GmbH.

Personalized medicine has continued its triumphant advance and is now widely used in diagnostics and therapy. The brochure provides information on:

  • the latest trends in personalized medicine
  • innovative and research-intensive Hessian companies
  • the current Hessian research landscape and networks
Read more about Personalisierte Medizin in Hessen - Company Profile bio.logis GIM >
Read more about DPD genetic testing before chemotherapy >
| Article
Sars-CoV-2 pandemic: importance of pharmacogenetics for therapy of mental and psychiatric disorders

Doctors point to an increase in psychological health problems and psychiatric illnesses such as depression and anxiety related to the Sars-CoV-2 pandemic. Initial studies document this development, which experts believe may further intensify after the pandemic has subsided.

Psychopharmaceuticals are an important component of the therapy of mental illnesses. Many weeks and months often pass before the right medication and the appropriate dose have been determined for a patient.

What many do not know: Antidepressants in particular contain active substances, the effects of which are influenced by variants in genes, which can delay or even prevent successful therapy. With pharmacogenetic tests, it is possible to individually check whether and which variants a person has. With this knowledge, the doctor can adapt the active ingredient or the dosage to the personal genetic situation. The GIMS.pharma software system from bio.logis can be used to provide the wealth of information required for clinical use.

Read more about Sars-CoV-2 pandemic: importance of pharmacogenetics for therapy of mental and psychiatric disorders >
| Press release
Euformatics and bio.logis collaborate to provide PGx results for NGS diagnostics

Euformatics partners with bio.logis to enable laboratories using its tertiary analysis platform to provide patients with pharmacogenomic dosing recommendations

Read more about Euformatics and bio.logis collaborate to provide PGx results for NGS diagnostics >
| Article
Pharmacogenomics for clinical use: digital and validated

Save the date: Learn more about upcoming congresses, where you can meet bio.logis and talk to our team ...

Read more about Pharmacogenomics for clinical use: digital and validated >
| Article
Pharmakogenetik: Medikamente dosieren – aber richtig!

Read full article on medinside, published Oct 20th.

Read more about Pharmakogenetik: Medikamente dosieren – aber richtig! >
| Article
GIMS.pharma supports implementation of pharmacogenomics at point of care

Medicines do not have the same effect on all patients. Because many factors affect drug response, physicians must select a drug that is appropriate for each individual and carefully adjust the dose. What many do not know and therefore often not considered in drug therapy: variants of DNA can lead to unwanted or insufficient drug effects (ADR). Get the whole story ....

Read more about GIMS.pharma supports implementation of pharmacogenomics at point of care >
| Article
Association for Molecular Pathology issues helpful Recommendations to Labs for Responsible PGx Test Offerings

The American AMP is responding with a position paper to the FDA-evoked discussions around PGx with clear recommendations on gene drug targets, laboratory and delivery of information for the POC.

Article on genomeweb
Association for Molecular Pathology Position Statement

Read more about Association for Molecular Pathology issues helpful Recommendations to Labs for Responsible PGx Test Offerings >